Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28940568 | 1.00 | L3MBTL1 (0.43) | L3MBTL1PPARAFFAR4AGTR2CTSS | |
| SCHEMBL26951492 | 1.00 | L3MBTL1 (0.43) | L3MBTL1PPARAFFAR4AGTR2CTSS | |
| SCHEMBL6407743 | 0.92 | FFAR4 (0.47) | PPARAFFAR4CTSSPPARG | |
| SCHEMBL28741127 | 0.88 | L3MBTL1 (0.46) | L3MBTL1PPARAAGTR2CTSSRAB9A | |
| SCHEMBL28741135 | 0.88 | L3MBTL1 (0.46) | L3MBTL1PPARAAGTR2CTSSRAB9A | |
| SCHEMBL28741137 | 0.88 | L3MBTL1 (0.46) | L3MBTL1PPARAAGTR2CTSSRAB9A | |
| SCHEMBL6409542 | 0.87 | L3MBTL1 (0.44) | L3MBTL1FFAR4RAB9AKMT2AALDH1A1 | |
| SCHEMBL6407549 | 0.84 | CPB1 (0.51) | FFAR4AGTR2ALDH1A1LMNA | |
| SCHEMBL17407791 | 0.84 | CPB1 (0.51) | FFAR4AGTR2ALDH1A1LMNA | |
| SCHEMBL23970542 | 0.82 | CA1 (0.49) | FFAR4AGTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | L3MBTL1 2735/4885PPARA 2618/4885FFAR4 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.